Recombinant DNA Advisory Committee - 12/1-2/94 
within the context of germ line alteration. Dr. Parkman said the immediate question for the RAC is the 
unintended germ line insertion of vector sequences, and the RAC has to develop guidelines for the 
forthcoming protocols with this unintended germ line alteration. Dr. Zallen said that the prenatal gene 
therapy is a very important area for the RAC. Ms. Meyers suggested a combined working group of prenatal 
and germ line gene therapy. Dr. Walters thanked Dr. Patterson for her excellent presentation. 
SUMMARY 
On December 2, Dr. Amy Patterson of FDA presented an overview of some of the ethical issues involving in 
utero cell and gene therapies. The RAC recommended the establishment of a subcommittee to examine the 
ethical issues involving in utero gene therapy. Since the issue of germ line gene therapy and transmission is 
closely related to the issue of in utero therapy, the subcommittee should analyze both issues and their 
interrelationship to each other. 
XVI. FUTURE MEETINGS OF THE RAC 
The next meeting of the RAC will be March 6-7, 1995, at the NIH, Building 31C, Conference Room 6, 
Bethesda, Maryland. 
XVII. ADJOURNMENT 
Dr. Walters adjourned the meeting at 3:50 p.m. on December 2, 1994. 
l^glson A. Wivel, M.D. ^ 
Executive Secretary 
I hereby acknowledge that, to the best of my knowledge, the 
foregoing Minutes and Attachments are accurate and 
complete. 
Patc: 3 
LeRoy B.*Walters, Ph.D. 
Chair 
Recombinant DNA Advisory Committee 
National Institutes of Health 
Recombinant DNA Research, Volume 20 
[481] 
